文献速递浆细胞疾病

多发性骨髓瘤进展过程中对蛋白酶体抑制剂、免疫调节药物和达雷妥尤单抗的体外耐药性检测

Measurement of ex vivo resistance to proteasome inhibitors, IMiDs, and daratumumab during multiple myeloma progression.
PubMed 文献 · Blood Adv · 2020-01-01

研究开发了骨髓瘤药物敏感性检测(My-DST),用未经筛选的骨髓单个核细胞与临床用药 panel 共培养,流式细胞术测骨髓瘤特异性细胞毒性,对 55 例初诊或复发原代样本进行 profiling。结果显示随病程进展对免疫调节药物、蛋白酶体抑制剂和达雷妥尤单抗的敏感性逐渐丧失,体外药敏对后续治疗临床反应有敏感性和特异性,My-DST 判定敏感药物少于 2 种者临床反应深度和持续时间较差。

要点

  • My-DST 用全骨髓培养可保持原代骨髓瘤细胞活力。
  • 随病程进展,对免疫调节药物、蛋白酶体抑制剂和达雷妥尤单抗的敏感性逐渐丧失。
  • My-DST 判定敏感药物少于 2 种者,临床反应深度和持续时间较差。

核心结论

  • 体外药敏具有预后影响,经进一步验证后可能有助于制定更个体化、更有效的治疗方案。

研究设计与样本

  • 开发功能学体外方法 My-DST,用未经筛选的骨髓单个核细胞与临床在用药物 panel 共培养,流式细胞术测骨髓瘤特异性细胞毒性。
  • 用 My-DST 对 55 例初诊或复发原代样本进行 profiling。
  • 每种药物的敏感性或耐药性由骨髓瘤细胞活力相对未处理对照样本的变化确定。

主要发现

  • My-DST 显示随病程进展对免疫调节药物、蛋白酶体抑制剂和达雷妥尤单抗的敏感性逐渐丧失,与临床耐药发展一致。
  • 前瞻性观察中,患者体外对后续接受药物的敏感性对临床反应具有敏感性和特异性。
  • My-DST 判定敏感药物少于 2 种的治疗,导致临床反应深度和持续时间较差。

关键数值与推荐

  • 全骨髓培养有助于保持原代骨髓瘤细胞活力。
  • 敏感性或耐药性由骨髓瘤细胞活力相对未处理对照样本的变化确定。

临床怎么用

  • 作者认为体外药敏具有预后影响,经进一步验证后可能有助于制定更个体化、更有效的治疗方案。

局限性

  • 原文结论提出需要进一步验证(with further validation)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The oncogenic drivers and progression factors in multiple myeloma (MM) are heterogeneous and difficult to target therapeutically. Many different MM drugs have emerged, however, that attack various phenotypic aspects of malignant plasma cells. These drugs are administered in numerous, seemingly interchangeable combinations. Although the availability of many treatment options is useful, no clinical test capable of optimizing and sequencing the treatment regimens for an individual patient is currently available. To overcome this problem, we developed a functional ex vivo approach to measure patients' inherent and acquired drug resistance. This method, which we termed myeloma drug sensitivity testing (My-DST), uses unselected bone marrow mononuclear cells with a panel of drugs in clinical use, followed by flow cytometry to measure myeloma-specific cytotoxicity. We found that using whole bone marrow cultures helped preserve primary MM cell viability. My-DST was used to profile 55 primary samples at diagnosis or at relapse. Sensitivity or resistance to each drug was determined from the change in MM viability relative to untreated control samples. My-DST identified progressive loss of sensitivity to immunomodulatory drugs, proteasome inhibitors, and daratumumab through the disease course, mirroring the clinical development of resistance. Prospectively, patients' ex vivo drug sensitivity to the drugs subsequently received was sensitive and specific for clinical response. In addition, treatment with <2 drugs identified as sensitive by My-DST led to inferior depth and duration of clinical response. In summary, ex vivo drug sensitivity is prognostically impactful and, with further validation, may facilitate more personalized and effective therapeutic regimens.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Walker ZJ, VanWyngarden MJ, Stevens BM, et al. Measurement of ex vivo resistance to proteasome inhibitors, IMiDs, and daratumumab during multiple myeloma progression. Blood Adv. 2020. PMID: 32311014. doi:10.1182/bloodadvances.2019000122

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。